As a co-inhibitory receptor that can be expressed on the surface of effector T and NK cells, it binds to the ligands CD155 and CD112 on the surface of myeloma cells (or antigen-presenting cells) by competing with its co-stimulatory counterpart CD226 (DNAM-1) [74]. This evidence concerns the gene PVR and plasma cell myeloma.